Bluebird Bio Reaffirms Support for Carlyle Deal Amid Lack of Binding Offer From Ayrmid

MT Newswires Live04-16

Bluebird Bio (BLUE) said Wednesday its board reaffirmed its support for its planned acquisition by Carlyle (CG) and SK Capital as Ayrmid has not sent a binding or fully financed offer after three weeks of engagement, including a timeline extension.

Bluebird said Ayrmid's proposal remained "highly conditional" even after it engaged with Ayrmid on two occasions.

The company said it has recommended that all stockholders tender by May 2 into the current agreement with Carlyle and SK Capital.

Under the deal announced in February, Bluebird agreed to be acquired and taken private by funds managed by Carlyle and SK Capital for $3 a share in cash and a one-time contingent value right of $6.84 a share payable upon achieving a net sales milestone.

Shares of Bluebird were down more than 6% in recent trading Wednesday.

Price: 4.19, Change: -0.28, Percent Change: -6.26

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2527407812?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-16 22:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2527407812","market":"us","top_or_hot":-1,"title":"Bluebird Bio Reaffirms Support for Carlyle Deal Amid Lack of Binding Offer From Ayrmid","media":"MT Newswires Live","content":"<html><body><p> Bluebird Bio (BLUE) said Wednesday its board reaffirmed its support for its planned acquisition by Carlyle (CG) and SK Capital as Ayrmid has not sent a binding or fully financed offer after three weeks of engagement, including a timeline extension.</p><p>Bluebird said Ayrmid's proposal remained \"highly conditional\" even after it engaged with Ayrmid on two occasions.</p><p>The company said it has recommended that all stockholders tender by May 2 into the current agreement with Carlyle and SK Capital.</p><p>Under the deal announced in February, Bluebird agreed to be acquired and taken private by funds managed by Carlyle and SK Capital for $3 a share in cash and a one-time contingent value right of $6.84 a share payable upon achieving a net sales milestone.</p><p>Shares of Bluebird were down more than 6% in recent trading Wednesday.</p><p>Price: 4.19, Change: -0.28, Percent Change: -6.26</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bluebird Bio Reaffirms Support for Carlyle Deal Amid Lack of Binding Offer From Ayrmid</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBluebird Bio Reaffirms Support for Carlyle Deal Amid Lack of Binding Offer From Ayrmid\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-16 22:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Bluebird Bio (BLUE) said Wednesday its board reaffirmed its support for its planned acquisition by Carlyle (CG) and SK Capital as Ayrmid has not sent a binding or fully financed offer after three weeks of engagement, including a timeline extension.</p><p>Bluebird said Ayrmid's proposal remained \"highly conditional\" even after it engaged with Ayrmid on two occasions.</p><p>The company said it has recommended that all stockholders tender by May 2 into the current agreement with Carlyle and SK Capital.</p><p>Under the deal announced in February, Bluebird agreed to be acquired and taken private by funds managed by Carlyle and SK Capital for $3 a share in cash and a one-time contingent value right of $6.84 a share payable upon achieving a net sales milestone.</p><p>Shares of Bluebird were down more than 6% in recent trading Wednesday.</p><p>Price: 4.19, Change: -0.28, Percent Change: -6.26</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2527407812","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2527407812","pubTimestamp":1744815503,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Bluebird Bio  said Wednesday its board reaffirmed its support for its planned acquisition by Carlyle  and SK Capital as Ayrmid has not sent a binding or fully financed offer after three weeks of engagement, including a timeline extension.Bluebird said Ayrmid's proposal remained \"highly conditional\" even after it engaged with Ayrmid on two occasions.The company said it has recommended that all stockholders tender by May 2 into the current agreement with Carlyle and SK Capital.Under the deal announced in February, Bluebird agreed to be acquired and taken private by funds managed by Carlyle and SK Capital for $3 a share in cash and a one-time contingent value right of $6.84 a share payable upon achieving a net sales milestone.Shares of Bluebird were down more than 6% in recent trading Wednesday.Price: 4.19, Change: -0.28, Percent Change: -6.26","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4578":"CAR-T","BK4556":"基因编辑","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4139":"生物科技","CG":"凯雷","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4135":"资产管理与托管银行"},"translate_title":"由于艾尔米德缺乏具有约束力的要约，蓝鸟生物重申支持凯雷交易","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLUE":0.9,"CG":0.9},"content_text":"Bluebird Bio (BLUE) said Wednesday its board reaffirmed its support for its planned acquisition by Carlyle (CG) and SK Capital as Ayrmid has not sent a binding or fully financed offer after three weeks of engagement, including a timeline extension.Bluebird said Ayrmid's proposal remained \"highly conditional\" even after it engaged with Ayrmid on two occasions.The company said it has recommended that all stockholders tender by May 2 into the current agreement with Carlyle and SK Capital.Under the deal announced in February, Bluebird agreed to be acquired and taken private by funds managed by Carlyle and SK Capital for $3 a share in cash and a one-time contingent value right of $6.84 a share payable upon achieving a net sales milestone.Shares of Bluebird were down more than 6% in recent trading Wednesday.Price: 4.19, Change: -0.28, Percent Change: -6.26","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2527407812","isCrawlerRequest":true}